India’s pharma exports stay resilient amid global headwinds, near $29 billion mark

Indian pharmaceutical exports are performing strongly. Shipments neared $29 billion by February this financial year. This growth continues despite global market volatility. Formulations, biologicals, vaccines, and Ayush products are leading the surge. The sector is poised for significant expansion by 2030. India remains a vital global supplier of affordable medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G42yv0f
via IFTTT

Govt orders safety review of popular weight-loss drugs amid rising demand

Indian authorities are increasing vigilance on popular weight loss drugs. The Indian Pharmacopoeia Commission will now compile reports on adverse events. This move aims to ensure safety and timely action. Generic versions of these drugs are expected to become widely available soon. Regulatory bodies are also cracking down on misleading advertisements for prescription medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zVMvPFC
via IFTTT

Why healthcare access still depends on affordability in India, and how universal insurance may change that

India's healthcare system faces affordability challenges despite infrastructure advancements, with out-of-pocket spending causing financial stress. Universal health insurance and digital integration are crucial for equitable access, preventive care, and a patient-focused model. Expanding infrastructure beyond metros and adopting holistic approaches are key to reducing inequality and improving outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UlEN6cY
via IFTTT

India's 'Mounjaro brides': Weight-loss injections become part of pre-wedding preparation

With wedding season in full swing, Indian health clinics are rolling out specialized weight-loss packages that include popular drugs such as Mounjaro and Wegovy. This emerging trend underscores the immense societal pressure to achieve a perfect look in a short span of time.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6JtLMfi
via IFTTT

Indian pharma sector faces supply risk amid West Asia conflict despite duty waiver

India's pharmaceutical industry faces ongoing concerns about securing essential petrochemical supplies due to the West Asia conflict. While a customs duty waiver offers some cost relief, industry experts highlight supply chain disruptions and timely movement as the primary challenges. The government's intervention aims to stabilize supply and lower input costs for critical sectors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rDa190b
via IFTTT

Emcure cuts semaglutide injection price by average 47%

The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg with the highest dose priced at Rs 8,999 for a month’s supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VXiEGxC
via IFTTT

Emcure slashes prices of weight management drug Poviztra by up to 55%

Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by up to 55 percent. This change begins on April 3, 2026. The aim is to help more people manage obesity. This move supports Emcure's commitment to better health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQmNeiH
via IFTTT

Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk

The US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Novo Nordisk in the GLP-1 medicine market. Foundayo is an oral medication offering a new option for weight management. Lilly plans to launch the pill soon, with further global approvals expected this year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VD9kGBq
via IFTTT

Govt cracks down on GLP-1 drugs: Safety first amid weight-loss hype

India's government has released strict rules for GLP-1 drugs, used for diabetes and obesity. These powerful medications are now prescription-only, requiring specialist doctors. Unsupervised sales are banned. Inspections are increasing, with penalties for rule-breakers. Patients must use these drugs only under medical care to avoid side effects. This move ensures safe use and protects public health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tRfbqPg
via IFTTT